AIM
CRSP icon

Advyzon Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Advyzon Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,869
Closed -$380K – 576
2025
Q3 		$380K Buy
5,869
+77
+1% +$4.42K 0.07% 268
2025
Q2 		$282K Buy
+5,792
New +$224K 0.06% 290

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
GP
GSK plc London $602M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advyzon Investment Management's CRSP Position: Q4 2025 in Review

Advyzon Investment Management sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 5,869 shares — an estimated $380K sold.

Advyzon Investment Management first reported a position in CRSP in Q2 2025 and held it in 2 quarters. The position peaked at $380K in Q3 2025. 480 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Advyzon Investment Management reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Advyzon Investment Management sold 5,869 CRISPR Therapeutics shares in Q4 2025, an estimated $380K.
  • Advyzon Investment Management first reported a position in CRISPR Therapeutics in Q2 2025 and held it in 2 quarters.
  • Advyzon Investment Management's CRISPR Therapeutics position peaked at $380K in Q3 2025.
  • 480 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Advyzon Investment Management's 13F filing for Q4 2025, filed 13 Feb 2026.